INDSWFTLAB379.00

Ind-Swift Laboratories Limited

· Pharma & Health
₹ CrorePeersSMSPHARMASOLARADCALHIKALUNICHEMLABGUFICBIOPANACEABIORPGLIFEMcap ₹3,291 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)6.37185.88198.70198.70
Receivable Days (DSO)48.19106.90113.00113.00
Payable Days (DPO)57.26179.46195.92184.80
Cash Conversion Cycle (days)-2.70113.32115.78126.90
Working Capital Turnover2.910.870.890.92
Asset Turnover1.100.390.380.38
Cash Conversion (CFO/Net Income)-0.43-0.10-1.53-1.53
CFO/EBITDA-0.711.31-1.40-1.40
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.